Search

Clinical trials

The advance of highly innovative, increasingly personalized therapies in hematology requires novel clinical trial designs and more flexible, adaptive regulatory frameworks and improved data generation to support decision making both during and after clinical studies.

Read more

Health Technology Assessment (HTA)

Every European citizen should have access to the best quality medical care at the best possible price. Pan-European cooperation on health technology assessments (HTA) is essential for such aspirations.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

Read more

EHA undersigns Manifesto on Treatment Optimization

EHA has given its formal endorsement to the “Manifesto for a new approach for better medicine in Europe: Establishing Treatment Optimization as part of personalized medicine development”.

Read more

EU Elections and Health Policy

HemAffairs Article #1 – June 2019

2019 will see significant changes within the European institutions.

Read more

PRESS RELEASE: Cyprus Presidency promotes win-win on health and competitiveness

The report, “Building an Open Innovation ecosystem in Europe for healthcare”, will be launched at a press conference in the European Parliament in Brussels on 29 November, 2012.

Read more